Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus | Zendy

Warren E. Rose | Zendy; Rochelle Knier | Zendy; Paul R. Hutson | Zendy

Open Access

Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus

Author(s) -

Warren E. Rose,

Rochelle Knier,

Paul R. Hutson

Publication year - 2010

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq292

Subject(s) - vancomycin , pharmacodynamics , staphylococcus aureus , medicine , population , pharmacokinetics , methicillin resistant staphylococcus aureus , antibiotics , microbiology and biotechnology , minimum inhibitory concentration , antibacterial agent , pharmacology , biology , bacteria , environmental health , genetics

Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) have a higher predisposition to select for VISA with thickened cell walls upon vancomycin exposure, but the pharmacodynamic relationship of this occurrence with clinical doses is unknown. This study investigates the impact of clinical vancomycin dose simulations on cell wall thickness (CWT) and the emergence of resistance in hVISA in an in vitro pharmacodynamic model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research